Comparative analysis of the use of technetium-99m labeled recombinant target molecules at doses of 1000 and 2000 μg for radionuclide diagnostics of HER2-positive breast cancer. (2022). Voprosy Onkologii, 68(1), 60-65. https://doi.org/10.37469/0507-3758-2022-68-1-60-65